

National Center for Quality Control of Skin and Sexually Transmitted Diseases
Baseline Survey Questionnaire (2024)

General Instructions Before Filling Out the Form:

1. This baseline survey focuses on the clinical service capabilities and resource allocation for four specific diseases/technologies: psoriasis, atopic dermatitis, lupus erythematosus, and dermatologic imaging.
2. Some information may require coordination with other hospital departments (e.g., obtaining data from the Information Department, drug information from the Pharmacy Department) or other specialties (e.g., lupus erythematosus data may need to be obtained from Rheumatology or other departments).
3. For data that cannot be obtained despite maximum effort, please fill in "No Data" instead of "0".
4. The baseline survey covers the period from January 1, 2023, to December 31, 2023.

I. Basic Information of the Dermatology Department

- ✓ Province: _____; City: _____ (Fill in)
- ✓ Hospital Name: _____; Hospital Level: _____ (Fill in)
- ✓ Department Director Contact Person: _____; Mobile Number: _____; Email: _____ (Fill in)
- ✓ Number of Doctors in the Department: _____; Number of Doctors with Senior Titles (Associate Professor or Above): _____; Number of Nurses: _____; Number of Medical Technicians: _____ (Fill in)
- ✓ Number of Consultation Desks: _____; Number of Beds: _____ (Fill in)

II. Specialized Disease Clinical Service Capabilities

(1) Psoriasis

- ✓ Is there a specialized psoriasis clinic?: (1) Yes (2) No (Dropdown selection)
- ✓ Is there an electronic medical record system for psoriasis?: (1) Yes (2) No (Dropdown selection)

- ✓ Weekly frequency of specialized psoriasis clinic: _____; Weekly number of psoriasis patients: _____ (Fill in)
- ✓ Total outpatient visits in 2023: _____; Of which diagnosed with psoriasis: _____; Of which diagnosed with plaque psoriasis: _____; Of which diagnosed with moderate-to-severe plaque psoriasis: _____ (Fill in)
- ✓ Total inpatients in 2023: _____; Of which diagnosed with psoriasis: _____; Of which diagnosed with plaque psoriasis: _____; Of which diagnosed with moderate-to-severe plaque psoriasis: _____ (Fill in)
- ✓ Psoriasis severity assessment methods used: (1) Not assessed (2) PASI (3) PGA (4) DLQI (5) BSA (Dropdown selection)
- ✓ Is special site involvement assessed?: (1) Yes (2) No (Dropdown selection)
- ✓ Is personal comorbidity history recorded?: (1) Yes (2) No (Dropdown selection)
- ✓ Is dermatologic imaging used for disease assessment and/or differential diagnosis?: (1) Yes (2) No (Dropdown selection)
- ✓ Is pre-treatment screening conducted for immunosuppressive agents, biologics, or small molecule targeted drugs?: (1) Yes (2) No (Dropdown selection)
- ✓ Is screening conducted during the use of immunosuppressive agents, biologics, or small molecule targeted drugs?: (1) Yes (2) No (Dropdown selection)

(2) Atopic Dermatitis

- ✓ Is there a specialized atopic dermatitis clinic?: (1) Yes (2) No (Dropdown selection)
- ✓ Is there an electronic medical record system for atopic dermatitis?: (1) Yes (2) No (Dropdown selection)
- ✓ Weekly frequency of specialized atopic dermatitis clinic: _____; Weekly number of atopic dermatitis patients: _____ (Fill in)
- ✓ Total outpatient diagnoses of atopic dermatitis in 2023: _____; Diagnosed with eczema: _____ (Fill in)
- ✓ Total discharged patients diagnosed with atopic dermatitis in 2023: _____; Diagnosed with eczema: _____ (Fill in)
- ✓ Is the principle of step-wise treatment followed?: (1) Yes (2) No (Dropdown selection)

- ✓ Is proactive maintenance therapy with topical medications conducted?: (1) Yes (2) No (Dropdown selection)
- ✓ Are treatments such as UV phototherapy or wet wrap therapy conducted?: (1) Yes (2) No (Dropdown selection)
- ✓ Atopic dermatitis severity assessment methods used: (1) Not assessed (2) IGA (3) EASI (4) SCORAD (5) BSA (Dropdown selection)
- ✓ Patient-reported severity assessment methods used: (1) Not assessed (2) NRS or VAS (3) POEM (4) DLQI (5) ADCT (Dropdown selection)
- ✓ Is personal atopic comorbidity history recorded?: (1) Yes (2) No (Dropdown selection)
- ✓ Are baseline comorbidities recorded?: (1) Yes (2) No (Dropdown selection)
- ✓ Is family history recorded?: (1) Yes (2) No (Dropdown selection)
- ✓ Are auxiliary tests conducted for disease assessment and/or differential diagnosis of moderate-to-severe atopic dermatitis?: (1) Yes (2) No (Dropdown selection)
- ✓ Is pre-treatment screening conducted for immunosuppressive agents, biologics, or small molecule targeted drugs?: (1) Yes (2) No (Dropdown selection)
- ✓ Is screening conducted during the use of immunosuppressive agents, biologics, or small molecule targeted drugs?: (1) Yes (2) No (Dropdown selection)

(3) Lupus Erythematosus (Please provide the best lupus erythematosus diagnosis and treatment information for the entire hospital after consulting with relevant departments such as Dermatology, Rheumatology, Nephrology, Pediatrics, Neurology, etc. Refer to the appendix for screening methods and definitions of lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, and cutaneous lupus erythematosus.)

- ✓ Specialized lupus erythematosus clinic setup (multiple choice): (1) Dermatology (2) Rheumatology (3) Nephrology (4) Pediatrics (5) Neurology (6) Other specialties, specify: _____ (7) Not established
- ✓ Is there an electronic medical record system for lupus erythematosus?: (1) Yes (2) No (Dropdown selection)

- ✓ Is there a situation where lupus erythematosus clinical medication is limited and cannot meet daily treatment needs?: (1) Yes (2) No (Dropdown selection)
- ✓ Total outpatient diagnoses of lupus erythematosus in 2023: _____; Of which diagnosed with systemic lupus erythematosus: _____; Diagnosed with discoid lupus erythematosus: _____; Diagnosed with various types of cutaneous lupus erythematosus: _____; Diagnosed with unspecified subtype lupus erythematosus: _____ (Fill in)
- ✓ Total outpatient diagnoses of lupus erythematosus in minors (under 18) in 2023: _____; Of which diagnosed with systemic lupus erythematosus: _____; Diagnosed with discoid lupus erythematosus: _____; Diagnosed with various types of cutaneous lupus erythematosus: _____; Diagnosed with unspecified subtype lupus erythematosus: _____ (Fill in)
- ✓ Lupus erythematosus-related tests available or stably conducted through third parties (multiple choice): (1) Immunoglobulin testing (2) Antinuclear antibody (ANA) qualitative testing (3) ANA titer testing (4) Anti-double-stranded DNA antibody testing (5) Anti-ENA antibody testing (6) Anticardiolipin antibody testing (7) Lupus anticoagulant testing (8) Anti- β 2 glycoprotein I antibody testing (9) Rapid plasma reagin test for syphilis (10) Urine sediment testing (11) Urine microalbumin testing (12) 24-hour urine protein testing (13) Complement C3, C4 testing (14) Direct Coombs test (15) Skin HE staining (16) Skin immunofluorescence testing (lupus band test) (17) Kidney HE staining (18) Kidney immunofluorescence testing (19) Kidney electron microscopy (20) None of the above tests conducted
- ✓ Traditional drugs used for lupus erythematosus treatment (multiple choice): (1) Hydroxychloroquine (2) Thalidomide (3) Lenalidomide (4) Dapsone (5) Retinoids (6) Glucocorticoids (7) Methotrexate (8) Cyclophosphamide (9) Mycophenolate mofetil/mycophenolic acid (10) Cyclosporine (11) Tacrolimus (12) Azathioprine (13) Leflunomide (14) Tripterygium wilfordii/tripterygium glycosides (15) Nonsteroidal anti-inflammatory drugs (NSAIDs)
- ✓ Biologics used for lupus erythematosus treatment (multiple choice): (1) Belimumab (2) Telitacicept (3) Anifrolumab (4) Rituximab (5) Ocrelizumab (6) Eculizumab (7) No

biologics

- ✓ Small molecule drugs used for lupus erythematosus treatment (multiple choice): (1) Baricitinib (2) Tofacitinib (3) Upadacitinib (4) Abrocitinib (5) Ruxolitinib (6) Deucravacitinib (7) Bortezomib (8) No small molecule drugs
- ✓ Treatment methods used for lupus erythematosus (multiple choice): (1) High-dose glucocorticoid pulse therapy (2) Immunoglobulin pulse therapy (3) Plasma exchange therapy (4) Mesenchymal stem cell therapy (5) Autologous stem cell therapy (6) CAR-T therapy (7) None of the above therapies conducted
- ✓ Lupus erythematosus activity or severity assessment methods conducted (multiple choice): (1) Not assessed (2) SLEDAI-2K (3) BILAG (4) PGA or IGA (5) RECLASI (6) BSA
- ✓ Pre-treatment screening for immunosuppressive agents, biologics, or small molecule targeted drugs includes (multiple choice): (1) No pre-treatment screening (2) Complete blood count (3) Liver function (4) Kidney function (5) HBV/HCV serology testing (6) HIV serology testing (7) Urine pregnancy test (8) PPD/T-Spot/Quantiferon Gold tuberculosis-related testing (9) ANA (10) Tumor marker testing (11) Chest X-ray or CT (12) Drug genotyping (e.g., TPMT genotyping/activity testing before azathioprine treatment), specify: _____ (13) Other tests, specify: _____
- ✓ Screening during the use of immunosuppressive agents, biologics, or small molecule targeted drugs includes (multiple choice): (1) No monitoring during treatment (2) Complete blood count (3) Liver function (4) Kidney function (5) HBV/HCV serology testing (6) HIV serology testing (7) PPD/T-Spot/Quantiferon Gold tuberculosis-related testing (8) ANA (9) Tumor marker testing (10) Chest X-ray/CT (11) Drug concentration monitoring, specify drugs: _____ (12) Other tests, specify: _____

III. Resource Allocation

(1) Dermatologic Imaging Equipment

- ✓ Dermatoscope: (1) Available (2) Not available (Dropdown selection; if available, specify model: _____)

- ✓ Annual dermatoscope examination cases: _____ (Fill in)
- ✓ Confocal microscope for skin: (1) Available (2) Not available (Dropdown selection; if available, specify model: _____)
- ✓ Annual confocal microscope examination cases: _____ (Fill in)
- ✓ Skin ultrasound: (1) Available (2) Not available (Dropdown selection; if available, specify model: _____)
- ✓ Annual skin ultrasound examination cases: _____ (Fill in)
- ✓ Have dermatologic imaging operators participated in standardized training?: (1) All participated (2) Some participated (3) None participated (Dropdown selection)
- ✓ Number of department personnel certified in dermatoscope or confocal microscope imaging skills: Basic level: _____ persons, Intermediate level: _____ persons (Fill in)
- ✓ Dermatologic imaging database connectivity (multiple choice): (1) Managed by imaging operators (2) Departmental database (3) Hospital database (4) Multi-center sharing (5) No dermatologic imaging database established (Dropdown selection)
- ✓ Has the department established a quality control system for dermatologic imaging?: (1) Yes (2) No (Dropdown selection)
- ✓ Does the hospital have a telemedicine platform?: (1) Yes (2) No (Dropdown selection)
- ✓ Does the department conduct dermatology telemedicine?: (1) Yes (2) No (Dropdown selection)
- ✓ Does the hospital have an internet hospital?: (1) Yes (2) No (Dropdown selection)
- ✓ Does the department conduct internet-based medical consultations?: (1) Yes (2) No (Dropdown selection)
- ✓ Monthly outpatient volume for internet-based consultations: (1) Below 500 visits (2) 500-1,000 visits (3) 1,000-5,000 visits (4) Over 5,000 visits (Dropdown selection)

(2) Drug Availability

① Topical Drugs

- ✓ Vitamin D3 derivatives: (1) Available (2) Not available (Dropdown selection)
- ✓ Glucocorticoids: (1) Available (2) Not available (Dropdown selection)

- ✓ Calcineurin inhibitors: (1) Available (2) Not available (Dropdown selection)
- ✓ Tapinarof: (1) Available (2) Not available (Dropdown selection)

② Systemic Drugs

- ✓ Antiviral drugs: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ Antifungal drugs: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ Immunosuppressants: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ Retinoids: (1) Available (2) Not available (Dropdown selection)
- ✓ Nonsteroidal anti-inflammatory drugs (NSAIDs): (1) Available (2) Not available (Dropdown selection)
- ✓ Antimalarial drugs: (1) Available (2) Not available (Dropdown selection)
- ✓ Antiallergic drugs: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ TNF- α inhibitors: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ IL-4/IL-13 inhibitors: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ IL-17 inhibitors: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ IL-23 inhibitors: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ IgE inhibitors: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)
- ✓ Small molecule drugs: (1) Available (2) Not available (Dropdown selection; if available, specify types: _____)

(3) Technical Equipment

- ✓ Cryotherapy: (1) Available (2) Not available (Dropdown selection)
- ✓ Photodynamic therapy: (1) Available (2) Not available (Dropdown selection)
- ✓ Local injection therapy: (1) Available (2) Not available (Dropdown selection)
- ✓ Laser therapy: (1) Available (2) Not available (Dropdown selection)
- ✓ Plasma exchange: (1) Available (2) Not available (Dropdown selection)
- ✓ Dialysis: (1) Available (2) Not available (Dropdown selection)

(4) Patient Education Resources

- ✓ Is specialized disease patient education conducted?: (1) Yes (2) No (Dropdown selection)
- ✓ Forms of patient education (multiple choice): (1) Verbal education during consultations (2) Educational booklets or flyers (3) Online articles (4) Online short videos (5) Offline classes or lectures (6) Other, specify: _____ (Dropdown selection)

IV. Development Suggestions

What challenges and development needs do you believe currently exist?

- ✓ Talent team building: (1) Needed (2) Not needed (Dropdown selection)
- ✓ More training opportunities: (1) Needed (2) Not needed (Dropdown selection)
- ✓ Enhanced equipment allocation: (1) Needed (2) Not needed (Dropdown selection)
- ✓ Enhanced drug availability: (1) Needed (2) Not needed (Dropdown selection)
- ✓ Improved patient education capabilities: (1) Needed (2) Not needed (Dropdown selection)
- ✓ Other (please specify): _____